Last reviewed · How we verify

Therapeutic entecavir — Competitive Intelligence Brief

Therapeutic entecavir (Therapeutic entecavir) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside analog reverse transcriptase inhibitor (NRTI). Area: Infectious Disease.

marketed Nucleoside analog reverse transcriptase inhibitor (NRTI) HBV DNA polymerase Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Therapeutic entecavir (Therapeutic entecavir) — Taipei Veterans General Hospital, Taiwan. Entecavir is a guanosine nucleoside analog that selectively inhibits the replication of hepatitis B virus (HBV) DNA polymerase.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Therapeutic entecavir TARGET Therapeutic entecavir Taipei Veterans General Hospital, Taiwan marketed Nucleoside analog reverse transcriptase inhibitor (NRTI) HBV DNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside analog reverse transcriptase inhibitor (NRTI) class)

  1. Taipei Veterans General Hospital, Taiwan · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Therapeutic entecavir — Competitive Intelligence Brief. https://druglandscape.com/ci/therapeutic-entecavir. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: